COVID-19 trials registries data warehouse

http://en.irct.ir/trial/46875

Mohammadali Sahraian, Research Deputy

tums_edu@tumc.ac.ir

2020-04-09

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Treatment

2019-nCov (SARA-Cov-2) nucleic acid positive will be detected by PCR in affected patients older than 17 years old and younger than 76 years old. No medications or disorders that would affect vitamin D metabolism Women must be not pregnant at baseline and during study Ability and willingness to give informed consent and comply with protocol requirements

Ongoing treatment with pharmacologic doses of vitamin D, vitamin D metabolites or analogues Pregnant or lactating women; Severe underlying diseases, such as advanced malignant tumor, end-stage lung disease, etc. History of elevated serum calcium >9.8 mg/dl) Chronic hepatic or renal failure or patients with reduced kidney function, cancers, and malabsorption syndrome, a granulomatous disorders such as Sarcoidosis or Tuberculosis Supplementation with over the counter formulations of vitamin D2 or vitamin D3 Use of tanning bed or artificial UV exposure within the last two weeks. Consuming medication affecting bone metabolism (anti-convulsants, anti-tuberculosis medication, cimetidine, theophylline, and cholestyramine), as well as those who are following special diets such as vegetarian diet or consuming fortified products regularly. Subjects with a history of an adverse reaction to orally administered vitamin D, vitamin D metabolites or analogues. Inability to give informed consent

2

Tehran University of Medical Sciences

18

75

Iran

Mild disease at enrollment

1: Mild disease at enrollment

260

infection duration

Phase 3

[{"arm_notes": "", "treatment_id": 1370, "treatment_name": "Vitamin d", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]